J-Pharma Co (TSE:520A) EBIT per Share: 円 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:520A J-Pharma Co Ltd TSE:520A
9 GF Score
Price 円290.00
View Full Analysis

What is J-Pharma Co EBIT per Share?

J-Pharma Co TSE:520A -2.36% 9 EBIT per Share is 円 as of Dec. 2025. GuruFocus rates TSE:520A with a GF Score™ of 9/100. Among 1,173 Biotechnology companies, J-Pharma Co ranks worse than 85251.41% on this metric.

J-Pharma Co's EBIT per Share for the three months ended in Dec. 2025 was 円-27.18. J-Pharma Co does not have enough years/quarters to calculate its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for J-Pharma Co's EBIT per Share or its related term are showing as below:

TSE:520A's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

J-Pharma Co's EBIT for the three months ended in Dec. 2025 was 円-484.57 Mil.

J-Pharma Co  (TSE:520A) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

J-Pharma Co EBIT per Share Related Terms

J-Pharma Co EBIT per Share Historical Data

* Premium members only.

The historical data trend for J-Pharma Co's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

J-Pharma Co EBIT per Share Chart

J-Pharma Co Annual Data
Trend Mar24 Mar25
EBIT per Share
-91.68 -84.31

J-Pharma Co Quarterly Data
Mar24 Mar25 Dec25
EBIT per Share 0.00 0.00 -27.18
TSE:520A
9GF Score
J-Pharma Co Ltd TSE:520A
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

J-Pharma Co EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

J-Pharma Co's EBIT per Share for the fiscal year that ended in Mar. 2025 is calculated as

EBIT per Share(A: Mar. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-1503.199/17.830
=-84.31

J-Pharma Co's EBIT per Share for the quarter that ended in Dec. 2025 is calculated as

EBIT per Share(Q: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-484.574/17.830
=-27.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of 円 mean?
J-Pharma Co (TSE:520A) has a EBIT per Share of 円 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on J-Pharma Co and its competitors. According to the industry distribution chart, J-Pharma Co ranks #999999 out of 1173 companies in the Biotechnology industry.
Is J-Pharma Co's EBIT per Share too high?
J-Pharma Co's current EBIT per Share is 円. Based on the distribution chart, J-Pharma Co ranks #999999 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, J-Pharma Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does J-Pharma Co's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, J-Pharma Co ranks #999999 out of 1173 companies for EBIT per Share. This places J-Pharma Co in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on J-Pharma Co and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. J-Pharma Co's current EBIT per Share is 円. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J-Pharma Co stock overvalued right now?
J-Pharma Co (TSE:520A) has a current EBIT per Share of 円. The current EBIT per Share is 円. J-Pharma Co's overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For J-Pharma Co (TSE:520A), the current EBIT per Share is 円 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

J-Pharma Co Business Description

Address 1-10-11, HamamatsuCho, 8th floor, Minato-Ku, Tokyo, JPN, 105-0013
J-Pharma Co Ltd is engaged in the Drug discovery and development targeting SLC transporters. It is focused on a single segment of the drug discovery business, focusing on R&D and clinical development. The company's two compounds in clinical development are Nanbran Latte (JPH203) and JPH034.
9GF Score

Get the complete analysis for TSE:520A

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円290.00
Price